Jim R Beitel

This inventor holds 10 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Biomarin Pharmaceutical Inc., Zacharon Pharmaceuticals, Inc.. Active years: 2012-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jim R Beitel. Retrieved from https://idiyas.com/inventor/jim-r-beitel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 5.0

ph-index = 5

Forward Citations = 74(Granted Patents)

Location History:

San Diego, CA (US) (2012 - 2020)
Novato, CA (US) (2016 - 2020)

Company Filing History:

9 out of 137

Biomarin Pharmaceutical Inc.

patents

1 out of 2

Zacharon Pharmaceuticals, Inc.

patents

Years Active: 2012-2020

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10793894 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2020-10-06),

2. 10677786 - Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2020-06-09),

3. 10260084 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2019-04-16),

4. 9915649 - Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA (2018-03-13),

5. 9677116 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2017-06-13),

6. 9340822 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2016-05-17),

7. 9222120 - Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition (2015-12-29),

8. 8809009 - Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker (2014-08-19),

9. 8771974 - Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder (2014-07-08),

10. 8232073 - Quantification of non-reducing end glycan residual compounds (2012-07-31),

Title: Jim R Beitel: Innovator in Glycan Research

Introduction

Jim R Beitel is a prominent inventor based in San Diego, CA (US), known for his significant contributions to the field of glycan research. With a total of 10 patents, Beitel has made strides in developing methods for diagnosing and monitoring diseases associated with abnormal glycan accumulation.

Latest Patents

Among his latest patents, Beitel has developed methods for the quantification of non-reducing end glycan residual compounds. These methods are crucial for determining the presence, identity, or severity of various diseases or conditions. Additionally, he has created methods specifically for diagnosing and monitoring the treatment of mucopolysaccharidosis (MPS) I. These innovations involve quantifying a non-reducing end glycan residual compound and comparing it to a second biomarker, providing valuable insights into the management of MPS I.

Career Highlights

Throughout his career, Jim R Beitel has worked with notable companies such as BioMarin Pharmaceutical Inc. and Zacharon Pharmaceuticals, Inc. His work in these organizations has furthered the understanding of glycan-related disorders and has contributed to advancements in therapeutic approaches.

Collaborations

Beitel has collaborated with esteemed colleagues, including Brett E Crawford and Charles A Glass. These partnerships have enhanced his research and innovation efforts in the field.

Conclusion

Jim R Beitel's work in glycan research exemplifies the impact of innovation in medical diagnostics and treatment. His patents and collaborations continue to influence the landscape of disease management related to glycan accumulation.

Profile summary based on public USPTO records.